Olema Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) will participate in three upcoming investor healthcare conferences, each in a fireside chat format.
Events include the TD Cowen Oncology Innovation Summit on May 26, 2026 (virtual), Jefferies Global Healthcare Conference on June 3, 2026 in New York, and Goldman Sachs Global Healthcare Conference on June 9, 2026 in Miami. Webcasts will be accessible via Olema’s investor relations website, subject to host permissions.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
In the May 20 session, OLMA gained 6.56%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
TD Cowen 7th Annual Oncology Innovation Summit
Date and Time: May 26, 2026 at 12:30 p.m. ET
Format: Fireside Chat
Location: Virtual
Jefferies Global Healthcare Conference
Date and Time: June 3, 2026 at 8:45 a.m. ET
Format: Fireside Chat
Location: New York, NY
Goldman Sachs 47th Annual Global Healthcare Conference
Date and Time: June 9, 2026 at 3:20 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
